NICE IDs/GIDs

25/09/2026

ID6363: Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments

25/09/2026

ID6598: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over (review of HST31)

22/09/2026

ID6425: Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment

18/09/2026

ID6593: Plozasiran for treating familial chylomicronaemia syndrome

18/09/2026

ID6585: Olezarsen for treating familial chylomicronaemia syndrome

17/09/2026

GID-TA12551: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (rapid review of TA992)

14/09/2026

ID6453: Nirogacestat for treating desmoid tumours

10/09/2026

ID6299: Upadacitinib for treating giant cell arteritis

03/09/2026

ID6249: Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable

28/08/2026

ID6618: Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1

26/08/2026

ID6596: Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable

14/08/2026

ID6499: Insulin efsitora alfa for treating type 2 diabetes

11/08/2026

ID6537: Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years

11/08/2026

ID6510: 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years

31/07/2026

ID6232: Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia

29/07/2026

ID6155: Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma

29/07/2026

ID6413: Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments

28/07/2026

ID6451: Nemolizumab for treating prurigo nodularis

24/07/2026

ID6326: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779)

24/07/2026

ID6457: Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over